CONTEXT: Autoantibodies directed against the calcium-sensing receptor (CaSR) have been reported in several individuals with various autoimmune disorders and PTH-mediated hypercalcemia. Previously, glucocorticoid treatment has been shown to decrease the CaSR autoantibody titers and normalize the hypercalcemia in a patient with autoimmune hypocalciuric hypercalcemia (AHH). OBJECTIVE: The objective of the study was to evaluate a patient with AHH for the presence of blocking autoantibodies against the CaSR and to monitor her biochemical and serological responses to a trial of glucocorticoid therapy. RESULTS: Glucocorticoid treatment had no effect on serum total or ionized calcium concentration or serum PTH levels, all of which remained at higher than normal levels. In contrast, on prednisone, urinary calcium excretion increased from overtly hypocalciuric levels to normal values. Anti-CaSR autoantibodies were detected at similar levels in the patient's serum before, during, and after glucocorticoid treatment. Functional testing of these antibodies showed that they inhibited the stimulatory effect of extracellular Ca(2+) on ERK1/2 but did not suppress the calcium-induced accumulation of inositol-1-phosphate. CONCLUSIONS: We report a patient with AHH with frankly elevated PTH levels who was found to have autoantibodies against the CaSR. The hypercalcemia and CaSR autoantibody titers failed to respond to glucocorticoid therapy, unlike a previously reported patient with similar clinical and biochemical features. The anti-CaSR antibody-mediated inhibition of CaSR-stimulated ERK1/2 activity, but not of inositol-1-phosphate accumulation, suggests that ERK1/2 may mediate, at least in part, the regulation of PTH secretion and urinary calcium excretion by the CaSR.
CONTEXT: Autoantibodies directed against the calcium-sensing receptor (CaSR) have been reported in several individuals with various autoimmune disorders and PTH-mediated hypercalcemia. Previously, glucocorticoid treatment has been shown to decrease the CaSR autoantibody titers and normalize the hypercalcemia in a patient with autoimmune hypocalciuric hypercalcemia (AHH). OBJECTIVE: The objective of the study was to evaluate a patient with AHH for the presence of blocking autoantibodies against the CaSR and to monitor her biochemical and serological responses to a trial of glucocorticoid therapy. RESULTS: Glucocorticoid treatment had no effect on serum total or ionizedcalcium concentration or serum PTH levels, all of which remained at higher than normal levels. In contrast, on prednisone, urinary calcium excretion increased from overtly hypocalciuric levels to normal values. Anti-CaSR autoantibodies were detected at similar levels in the patient's serum before, during, and after glucocorticoid treatment. Functional testing of these antibodies showed that they inhibited the stimulatory effect of extracellular Ca(2+) on ERK1/2 but did not suppress the calcium-induced accumulation of inositol-1-phosphate. CONCLUSIONS: We report a patient with AHH with frankly elevated PTH levels who was found to have autoantibodies against the CaSR. The hypercalcemia and CaSR autoantibody titers failed to respond to glucocorticoid therapy, unlike a previously reported patient with similar clinical and biochemical features. The anti-CaSR antibody-mediated inhibition of CaSR-stimulated ERK1/2 activity, but not of inositol-1-phosphate accumulation, suggests that ERK1/2 may mediate, at least in part, the regulation of PTH secretion and urinary calcium excretion by the CaSR.
Authors: Olga Kifor; Aidan McElduff; Meryl S LeBoff; Francis D Moore; Robert Butters; Ping Gao; Thomas L Cantor; Imre Kifor; Edward M Brown Journal: J Clin Endocrinol Metab Date: 2004-02 Impact factor: 5.958
Authors: Pascal Joly; Jean-Claude Roujeau; Jacques Benichou; Catherine Picard; Brigitte Dreno; Emmanuel Delaporte; Loic Vaillant; Michel D'Incan; Patrice Plantin; Christophe Bedane; Paul Young; Philippe Bernard Journal: N Engl J Med Date: 2002-01-31 Impact factor: 91.245
Authors: M L Brandi; G D Aurbach; A Fattorossi; R Quarto; S J Marx; L A Fitzpatrick Journal: Proc Natl Acad Sci U S A Date: 1986-11 Impact factor: 11.205
Authors: Olga Kifor; Francis D Moore; Miriam Delaney; Jeffrey Garber; Geoffrey N Hendy; Robert Butters; Ping Gao; Thomas L Cantor; Imre Kifor; Edward M Brown; John Wysolmerski Journal: J Clin Endocrinol Metab Date: 2003-01 Impact factor: 5.958
Authors: D M Slovik; R M Neer; J L Ohman; F C Lowell; M B Clark; G V Segre; J T Potts Journal: Clin Endocrinol (Oxf) Date: 1980-03 Impact factor: 3.478
Authors: E Helen Kemp; Nikos G Gavalas; Samia Akhtar; Kai J E Krohn; J Carl Pallais; Edward M Brown; Philip F Watson; Anthony P Weetman Journal: J Bone Miner Res Date: 2010-01 Impact factor: 6.741
Authors: Katie Leach; Fadil M Hannan; Tracy M Josephs; Andrew N Keller; Thor C Møller; Donald T Ward; Enikö Kallay; Rebecca S Mason; Rajesh V Thakker; Daniela Riccardi; Arthur D Conigrave; Hans Bräuner-Osborne Journal: Pharmacol Rev Date: 2020-07 Impact factor: 25.468